Skip to main content

Table 2 Most common adverse events

From: Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu– positive advanced breast cancer: results of the CECOG LaVie trial

  Grade 1/2 n (%) Grade 3 n (%) Grade 4 n (%) Total n (%)
Diarrhea 20 (17.1) 1 (0.9) 0 (0) 21 (17.9)
Neutropenia 9 (7.7) 1 (0.9) 0 (0) 10 (8.5)
Leucopenia 8 (6.8) 0 (0) 0 (0) 8 (6.8)
Increased alkaline phosphatase 3 (2.6) 1 (0.9) 0 (0) 4 (3.4)
Nausea 4 (3.4) 0 (0) 0 (0) 4 (3.4)
Fatigue 4 (3.4) 0 (0) 0 (0) 4 (3.4)